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The Role of PET/CT for Evaluating Breast
Cancer
Positron emission tomography combined with computed tomography (PET/CT)
has been receiving increasing attention during the recent years for making the
diagnosis, for determining the staging and for the follow-up of various malignan-
cies. The PET/CT findings of 58 breast cancer patients (age range: 34 79 years
old, mean age: 50 years) were retrospectively compared with the PET or CT
scans alone. PET/CT was found to be better than PET or CT alone for detecting
small tumors or multiple metastases, for accurately localizing lymph node metas-
tasis and for monitoring the response to chemotherapy in breast cancer patients.
maging modalities like computed tomography (CT) and magnetic
resonance (MR) imaging rely on detecting anatomic changes for the
diagnosis, staging and follow-up of cancer patients. However, positron
emission tomography (PET) has the ability to demonstrate abnormal metabolic
activity, and 18F-2-deoxy-D-glucose (FDG) PET provides important tumor-related
qualitative and quantitative metabolic information that may be critical for the diagno-
sis and follow-up (1 3). Moreover, the combination of PET and computed tomogra-
phy (PET/CT) allows the functional PET and anatomical CT images to be acquired
under identical conditions and then they are rapidly co-registered. This combined
system has advantages over CT alone as functional information is added to morpho-
logical data, and this combined system has advantages over PET alone because
pathological areas of tracer uptake are better localized and the image acquisition time
is reduced (4 7). Moreover, the limited specificity of PET that’s due to the increased
glucose metabolic activities of benign tumors and inflammatory tissues (such as those
of tuberculosis) can be partially overcome by PET/CT (8, 9).
In this study, we investigated the role of PET/CT for evaluating breast cancer.
PATIENT SELECTION
Fifty-eight female patients with known breast cancer (age range: 34 79 years old,
mean age: 50 years), and who underwent PET/CT examinations at our facility
between April 2003 and June 2005 were enrolled in this study. The PET/CT examina-
tions were performed for the initial tumor staging, for suspected recurrence after
breast operation and for follow-up after chemotherapy. 
PET/CT IMAGING
Whole-body PET/CT imaging was performed using a combined PET/CT scanner
(Gemini, Philips Medical Systems, Bothell, WA). The Gemini is an open PET/CT
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Isystem that combines a helical dual slice CT scanner and a
3D PET scanner equipped with its own transmission
source. The MX8000 EXP CT scanner is a dual slice system
with a detector that consists of 1,344 cadmium tungstate
elements. After having the patients fast for at least four
hours, they were administered an intravenous injection of
240 to 400 MBq (approximately 10 mCi) FDG; oral
contrast was not administered. The blood glucose levels
were checked in all the patients before FDG administra-
tion, and no patient had a blood glucose level that
exceeded 200 mg/dl. The CT images were acquired from
the cerebellum to the pelvis without intravenous contrast
media, and a whole-body emission PET scan was
performed for the same axial coverage. The PET, CT and
fused PET/CT images were generated and then reviewed
on a computer workstation.
ROLE OF PET/CT
Primary Tumor
The ability of PET to detect breast cancer depends on the
tumor’s size and histology. The sensitivity of PET has been
reported to be 68% for small (< 2 cm) tumors and 92% for
larger (2 5 cm) tumors (10), and its reported overall
accuracy for detecting in situ carcinomas is low (sensitivity:
2 25%). The major limitation of PET or PET/CT for
breast imaging is its poor detection rate for small breast
carcinomas and non-invasive breast cancers (Fig. 1). 
However, PET/CT has a role to play in a selected group
of patients, such as those with dense breasts or with
implants, for determining tumor multiplicity, for localizing
the primary tumor in those patients with metastases of a
breast origin when the mammography is indeterminate,
and for those patients whom biopsy is not a desirable
option (11, 12). PET/CT has a potential advantage over
PET for evaluating small lesions in which the uptake may
be artifactually lowered due to the partial volume effect of
PET because areas of mild hyperglycolytic activity can be
reliably assigned to normal or abnormal anatomical
structures (Fig. 2).
Regional Lymph Node Metastasis 
Axillary lymph node metastasis is an important factor
when determining the prognosis of patients. Breast cancer
patients with four or more involved axillary lymph nodes
have a significantly higher risk of recurrence (13). The
sensitivity and specificity of axillary PET imaging in breast
cancer patient have been reported as 79 94% and 86
92%, respectively (11, 14). PET/CT can accurately localize
and differentiate the metastatic and reactive lymph nodes
when CT shows multiple enlarged lymph nodes in the
axilla (Fig. 3).
The metastasis to the internal mammary or mediastinal
lymph nodes in breast cancer patients is often clinically
occult. The prevalence of abnormal findings for the
internal mammary or mediastinal lymph nodes by PET was
about twice than of conventional CT in those patients with
recurrent or metastatic breast cancer (15). In a study by
Tatsumi et al., although the sample number was small,
PET/CT appeared to be more useful than CT for evaluat-
ing the internal mammary and mediastinal lymph nodes
because the smaller lymph nodes sometimes produced
equivocal or negative CT findings (7) (Fig. 4). 
Distant Metastasis
Distant metastases from breast cancer are frequently
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Fig. 1. Ductal carcinoma in situ in a 49-year-old woman. 
A. Sonography shows a 2.5 cm sized hypoechoic mass with an indistinct margin in the left upper breast (arrows). 
B. The PET/CT image shows no evidence of FDG uptake in the left breast. Surgery revealed ductal carcinoma in situ. 
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Fig. 3. Axillary lymph node metastasis in a 45-year-old woman with
a 4 cm invasive ductal carcinoma. 
A. The PET image shows increased FDG uptake in the right breast
(black arrow) and axilla (white arrow).
B. The CT image shows two enlarged lymph nodes in the right
axilla (arrows).
C. The PET/CT image shows accurate localization of the metasta-
tic (white arrow, SUV = 9.9) and reactive (black arrow) lymph
nodes. Surgery revealed one metastatic lymph node out of the 21
excised axillary lymph nodes.
A
B
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Fig. 2. Invasive breast cancer in a 57-year-old woman. 
A. The mediolateral oblique view of the screening mammogram shows a 1.1 cm sized spiculated mass (arrow) in the left breast. 
B. The PET image shows faint FDG uptake (SUV = 1.2) (arrow) in the left breast. It is difficult to detect the lesion due to partial volume
averaging. 
C. The PET/CT image shows that the focal uptake (arrow) is localized to the left breast. 
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Fig. 4. Mediastinal lymph node metastasis in a 41-year-old woman
who had undergone left modified radical mastectomy 10 months
previously. 
A. The PET image shows multiple areas of increased uptake
(arrows) in the left upper chest. 
B. The CT image shows a small soft tissue density in the anterior
mediastinum (arrow). 
C. The PET/CT image shows co-registration of the FDG uptake
and the soft tissue density in the anterior mediastinum, suggesting
internal mammary lymph node metastases (arrow).
A
B
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Fig. 5. Multiple distant metastases in a 44-year-old woman with
bilateral breast cancer. 
A. The PET image shows multiple areas of FDG uptake in the
thorax and abdomen. 
B, C. The PET/CT images show high uptake in both breasts (white
arrows in B), the mediastinal lymph nodes (black arrows in B) and
the visceral organs (arrows in C).
A
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Cfound in the lungs, liver and bones. One advantage of
whole-body PET imaging over conventional imaging
modalities such as chest films, bone scanning, and abdomi-
nal ultrasound is its ability to detect metastasis at different
sites and organs during a single examination (Fig. 5). Moon
et al. found that whole-body PET imaging had high
diagnostic accuracy for patients with suspected recurrent
or metastatic breast carcinoma (16). Based on the number
of lesions, its sensitivity for detecting distant metastasis was
85% and its specificity was 79%. 
Cook et al. found that PET was superior to bone scintig-
raphy for detecting osteolytic breast cancer metastases (17)
(Fig. 6). In contrast, the osteoblastic metastases showed
lower metabolic activity and they were frequently
undetectable by PET (17, 18). Yet PET/CT can overcome
this limitation, and osteoblastic bone lesions, even if
negative on PET scans, can be identified on CT images
(Fig. 7).
Treatment Monitoring
To downstage primary tumors prior to surgery and to
abolish occult distant metastases, neoadjuvant chemother-
apy is now being increasingly used to manage patients with
large and locally advanced breast cancer. Moreover,
several studies have demonstrated that patients with
unresponsive tumor may achieve improved survival by
administering alternative chemotherapy and/or prolonged
courses of chemotherapy (19, 20). Considering the side
effects of chemotherapy, there is a need to quickly identify
the non-responding patients early in their treatment.    
At present, the anatomical imaging modalities are
commonly used to evaluate the response to treatment by
evaluating the changes of the tumor’s size. Nevertheless,
sequential measurement of tumor size frequently does not
allow the determination of early response. The effect of
PET for evaluating the response to treatment has already
been demonstrated for different types of neoplasm, includ-
ing breast cancer (Fig. 8). In a study by Smith et al, the
mean reduction in FDG uptake after the first cycle of
chemotherapy was significantly higher in the lesions that
showed a partial (p = 0.013), complete macroscopic (p =
0.003), or complete microscopic (p = 0.001) response than
PET/CT for Breast Cancer Evaluation
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Fig. 6. Bone metastases in a 47-year-old woman with breast cancer. 
A-C. The PET and PET/CT images show increased FDG uptake in the T5 (B) and L1 (C) vertebrae (arrows). Osteolytic changes
suggestive of bone metastases are seen on CT. 
A C
Bthat of the non-responsive lesions, as determined by
histopathological examinations (20). Rose et al. have
reported that after a single cycle of chemotherapy, PET
predicted the complete pathological response with a
sensitivity of 90% and specificity of 74%, and by using a
decrease of FDG uptake at the threshold of < 55%, as
compared with the baseline scan, all the responders were
correctly identified after the first treatment course (100%
sensitivity and 85% specificity) (21). 
PET/CT may also play a role in radiation therapy
planning by providing an accurate estimate of the extent of
tumor (22).
Recurrence
Detecting early recurrence has an important survival
benefit because it prompts clinical consideration for
administering different therapies. However, it is difficult to
differentiate true recurrence from postsurgical sequelae
and radiation sequelae with using just the conventional
imaging modalities. Locoregional recurrences predomi-
nately affect the breast, skin, the axillary and supraclavicu-
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Fig. 7. Bone metastases in a 64-year-old woman who had
undergone right modified radical mastectomy 36 months
previously. 
A. The bone scintigram shows increased FDG uptake in the right
1st and left 7th ribs (arrow), which is probably due to bony
metastases.
B. The PET/CT image shows no FDG uptake in the left 7th rib
(arrow).
C. The CT image shows an osteoblastic bony lesion in the left 7th
rib (arrow).
AB
C
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Fig. 6. D. The whole body Tc-99m bone scintigram obtained 7
days before the PET scan shows faint uptake in only the L1
vertebra (arrow). T5 metastasis is not visualized. 
E. The follow-up bone scintigram obtained three months later
shows foci of hot uptake in the T5 and L1 vertebrae (arrows).
PET/CT was superior to bone scintigram for the early detection of
osteolytic breast cancer metastasis.lar nodes, and the chest wall (23, 24).
Grahek et al. studied 134 patients with suspected
recurrence and they found that the sensitivity and
specificity of PET for detecting recurrence were 84% and
78%, respectively, whereas the sensitivities and specifici-
ties of the conventional imaging modalities were 63% and
61%, respectively (25). PET is considered to be highly
effective for evaluating patients with suspected recurrent
breast cancer, and it surpasses the other conventional
imaging modalities in terms of whole-body evaluation. The
CT data from a PET/CT examination allows the appropri-
ate anatomical localization of foci of FDG uptake (Fig. 9). 
CONCLUSION
The major roles for PET/CT in breast cancer are detect-
ing and localizing metastasis, monitoring the response to
treatment and early detection of recurrence. Yet the limita-
tion of PET/CT for breast imaging is its poor detection rate
for small breast carcinomas. 
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B, C. The PET images show focal high FDG uptake (SUV= 3.3)
(arrows) in the right chest wall. 
D. The PET/CT image shows a focus of high FDG uptake (arrow)
localized to the right pectoralis muscle. Accurate localization of the
lesion was difficult with using PET alone.
BC
D
AEremin O. Role of multimodality therapy in the management of
locally advanced carcinoma of the breast. J Am Coll Surg
1994;179:493-504 
20. Smith IC, Welch AE, Hutcheon AW, Miller ID, Payne S,
Chilcott F, et al. Positron emission tomography using [18F]-
fluorodeoxy-D-glucose to predict the pathologic response of
breast cancer to primary chemotherapy. J Clin Oncol 2000;18:
1676-1688
21. Rose C, Dose J, Avril N. Positron emission tomography for the
diagnosis of breast cancer. Nucl Med Commun 2002;23:613-618
22. Bradley J, Thorstad WL, Mutic S, Miller TR, Dehdashti F, Siegel
BA, et al. Impact of FDG-PET on radiation therapy volume
delineation in non-small-cell lung cancer. Int J Radiat Oncol
Biol Phys 2004;59:78-86
23. Eubank WB, Mankoff DA, Vesselle HJ, Eary JF, Schubert EK,
Dunnwald LK, et al. Detection of locoregional and distant
recurrences in breast cancer patients by using FDG PET.
RadioGraphics 2002;22:5-17
24. Kamby C, Vejborg I, Kristensen B, Olsen LO, Mouridsen HT.
Metastatic pattern in recurrent breast cancer. special reference
to intrathoracic recurrences. Cancer 1988;62:2226-2233
25. Grahek D, Montravers F, Kerrou K,Aide N, Lotz JP, Talbot JN.
[18 F]FDG in recurrent breast cancer: diagnostic performances,
clinical impact and relevance of induced changes in manage-
ment. Eur J Nucl Med Mol Imaging 2004;31:179-188
PET/CT for Breast Cancer Evaluation
Korean J Radiol 8(5), October 2007 437